1. Undercarboxylated osteocalcin has no adverse effect on endothelial function in rabbit aorta or human vascular cells
- Author
-
Saoirse E. O'Sullivan, Cassandra Smith, Anthony Zulli, Sophie A. Millar, Alan Hayes, Susan I. Anderson, Alexander Tacey, Itamar Levinger, and Tawar Qaradakhi
- Subjects
Male ,0301 basic medicine ,cell culture techniques ,medicine.medical_specialty ,Physiology ,Vasodilator Agents ,Osteocalcin ,Clinical Biochemistry ,Carbohydrate metabolism ,03 medical and health sciences ,0302 clinical medicine ,cardiovascular disease ,Original Research Articles ,Internal medicine ,medicine.artery ,Animals ,Humans ,Medicine ,Original Research Article ,Aorta, Abdominal ,Cells, Cultured ,Aorta ,biology ,business.industry ,Endothelial Cells ,Cell Biology ,Vasodilation ,Endothelial stem cell ,Glucose ,030104 developmental biology ,medicine.anatomical_structure ,Endocrinology ,Cell culture ,030220 oncology & carcinogenesis ,immunohistochemistry ,biology.protein ,Immunohistochemistry ,Rabbits ,business ,hyperglycaemia ,Ex vivo ,Blood vessel - Abstract
Undercarboxylated osteocalcin (ucOC) improves glucose metabolism; however, its effects on endothelial cell function are unclear. We examined the biological effect of ucOC on endothelial function in animal models ex vivo and human cells in vitro. Isometric tension and immunohistochemistry techniques were used on the aorta of male New Zealand white rabbits and cell culture techniques were used on human aortic endothelial cells (HAECs) to assess the effect of ucOC in normal and high‐glucose environments. Overall, ucOC, both 10 and 30 ng/ml, did not significantly alter acetylcholine‐induced blood vessel relaxation in rabbits (p > .05). UcOC treatment did not cause any significant changes in the immunoreactivity of cellular signalling markers (p > .05). In HAEC, ucOC did not change any of the assessed outcomes (p > .05). UcOC has no negative effects on endothelial function which is important to reduce the risks of off target adverse effects if it will be used as a therapeutic option for metabolic disease in the future., Undercarboxylated osteocalcin (ucOC) improves glucose metabolism; however, its effects on endothelial cell function are unclear. We examined the biological effect of ucOC on endothelial function in animal models ex vivo and human cells in vitro. We found that ucOC has no negative effects on endothelial function which is important to reduce the risks of off‐target adverse effects if it will be used as a therapeutic option for metabolic disease in the future.
- Published
- 2020